Shares of Baxter International BAX rose 1.2% in pre-market trading after the company reported Q3 results.
Earnings per share increased 16.90% year over year to $0.83, which beat the estimate of $0.73.
Revenue of $2,972,000,000 up by 4.24% year over year, which beat the estimate of $2,830,000,000.
The upcoming fiscal year's EPS expected to be between $3.02 and $3.05.
How To Listen To The Conference Call
Date: Oct 29, 2020
Time: 08:30 AM
ET Webcast URL: https://event.on24.com/eventRegistration/EventLobbyServlet?target=reg20.jsp&referrer=https%3A%2F%2Finvestor.baxter.com%2F&eventid=2624992&sessionid=1&key=4F06541584417F6BD91D46647C38B9CE®Tag=&sourcepage=register
52-week high: $95.19
Company's 52-week low was at $69.10
Price action over last quarter: down 8.29%
Baxter manufactures medical products across seven major reported business segments. The renal segment (32% of 2019 sales) includes peritoneal dialysis and hemodialysis products for chronically ill patients while its acute therapies segment (5%) offers kidney or other organ support tools in intensive care situations. The medication delivery segment (25% of sales) sells IV pumps, administrative sets, and solutions while its nutrition segment (8% of sales) offers parenteral nutrition therapies. The pharmaceuticals segment (19% of sales) offers injectable drugs, anesthetic gases, and compounding services. The advanced surgery segment (8% of sales) provides hemostastic products and biosurgical sealants. Contract manufacturing rounds out the remaining sales.
© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.